• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

一种用于从锕持续供应铋以用于靶向α治疗应用的电化学发生器。

An electrochemical generator for the continual supply of Bi from Ac for use in targeted alpha therapy applications.

作者信息

Forrester Ryan, Dutech Guy, Akin Andrew, Fassbender Michael E, Mastren Tara

机构信息

Nuclear Engineering Program, University of Utah, 110 Central Campus Dr, Salt Lake City, UT 84112, USA.

Chemistry Division, Los Alamos National Laboratory, PO Box 1663, Los Alamos, NM 87545, USA.

出版信息

Nucl Med Biol. 2024 Sep-Oct;136-137:108941. doi: 10.1016/j.nucmedbio.2024.108941. Epub 2024 Jul 9.

DOI:10.1016/j.nucmedbio.2024.108941
PMID:39002499
Abstract

Bismuth-213 is a radionuclide of interest for targeted alpha therapy and is supplied via a radiochemical generator system through the decay of Ac. Radionuclide generators employ longer lived "parent" radionuclides to routinely supply shorter-lived "daughter" radionuclides. The traditional Ac/Bi radiochemical generator relies on an organic cation exchange resin where Ac binds to the resin and Bi is routinely eluted. These resins degrade when they absorb large doses of ionizing radiation (>1 × 10 Gy/mg), which has been observed when the loading activity of Ac exceeds 2.59*10 Bq (70 mCi). Herein we report the development of an electrochemical generator for the supply of Bi that has the potential to overcome this limitation. Bismuth-213 spontaneously electrodeposits onto nickel foils in 0.1 M hydrochloric acid at 70 °C. Using this method, we were able to plate an average of 73 ± 4 % of the Bi in solution and obtain a final Bi recovery of 65 ± 8 % in 0.1 M citrate pH 4.5 via reverse electrolysis using titanium as the cathode. The recovered Bi had an average radiochemical purity of >99.8 % and was successfully used to radiolabel DOTATATE with an average radiochemical yield of 85.1 % (not optimized).

摘要

铋 - 213是一种用于靶向α治疗的放射性核素,通过锕的衰变经放射化学发生器系统供应。放射性核素发生器利用寿命较长的“母体”放射性核素来常规供应寿命较短的“子体”放射性核素。传统的锕/铋放射化学发生器依赖于有机阳离子交换树脂,其中锕与树脂结合,铋则常规洗脱。当这些树脂吸收大剂量电离辐射(>1×10 Gy/mg)时会发生降解,当锕的装载活度超过2.59×10 Bq(70 mCi)时就会观察到这种情况。在此,我们报告了一种用于供应铋的电化学发生器的开发,它有可能克服这一限制。铋 - 213在70°C的0.1 M盐酸中自发电沉积到镍箔上。使用这种方法,我们能够在溶液中平均电镀出73±4%的铋,并通过以钛为阴极的反向电解在0.1 M pH 4.5的柠檬酸盐中最终获得65±8% 的铋回收率。回收的铋平均放射化学纯度>99.8%,并成功用于标记DOTATATE,平均放射化学产率为85.1%(未优化)。

相似文献

1
An electrochemical generator for the continual supply of Bi from Ac for use in targeted alpha therapy applications.一种用于从锕持续供应铋以用于靶向α治疗应用的电化学发生器。
Nucl Med Biol. 2024 Sep-Oct;136-137:108941. doi: 10.1016/j.nucmedbio.2024.108941. Epub 2024 Jul 9.
2
Development of Ac/Bi generator based on α-ZrP-PAN composite for targeted alpha therapy.基于α-ZrP-PAN 复合材料的 Ac/Bi 发生器的靶向 α 治疗开发。
Nucl Med Biol. 2024 May-Jun;132-133:108909. doi: 10.1016/j.nucmedbio.2024.108909. Epub 2024 Mar 28.
3
A reverse U/Th radionuclide generator for targeted alpha therapy applications.一种用于靶向 alpha 治疗应用的反向 U/Th 放射性核素发生器。
Nucl Med Biol. 2020 Nov-Dec;90-91:69-73. doi: 10.1016/j.nucmedbio.2020.09.006. Epub 2020 Sep 30.
4
Bismuth-213 and actinium-225 -- generator performance and evolving therapeutic applications of two generator-derived alpha-emitting radioisotopes.铋 - 213和锕 - 225——两种基于发生器产生的α发射性放射性同位素的发生器性能及不断发展的治疗应用
Curr Radiopharm. 2012 Jul;5(3):221-7. doi: 10.2174/1874471011205030221.
5
The Evolving Clinical Role of Actinium-225 and Bismuth-213 for Targeted Alpha Therapy (TAT) - Production, Radiopharmaceutical Development and Clinical Applications.锕-225和铋-213在靶向α治疗(TAT)中的临床作用演变——生产、放射性药物研发及临床应用
Curr Radiopharm. 2018;11(3):154-155. doi: 10.2174/187447101103180911115600.
6
Targeted alpha therapy with bismuth-213 and actinium-225: Meeting future demand.使用铋-213和锕-225的靶向α疗法:满足未来需求。
J Labelled Comp Radiopharm. 2019 Sep;62(11):794-802. doi: 10.1002/jlcr.3792. Epub 2019 Aug 1.
7
Evaluation of nitrogen-rich macrocyclic ligands for the chelation of therapeutic bismuth radioisotopes.用于治疗性铋放射性同位素螯合的富氮大环配体的评估。
Nucl Med Biol. 2015 May;42(5):428-438. doi: 10.1016/j.nucmedbio.2014.12.007. Epub 2014 Dec 20.
8
Optimizing labelling conditions of Bi-DOTATATE for preclinical applications of peptide receptor targeted alpha therapy.优化用于肽受体靶向α治疗临床前应用的双功能奥曲肽(Bi-DOTATATE)标记条件。
EJNMMI Radiopharm Chem. 2017;1(1):9. doi: 10.1186/s41181-016-0014-4. Epub 2016 May 14.
9
An Overview of Targeted Alpha Therapy with Actinium and Bismuth.锕和铋靶向α治疗概述
Curr Radiopharm. 2018;11(3):200-208. doi: 10.2174/1874471011666180502104524.
10
LaPO4 nanoparticles doped with actinium-225 that partially sequester daughter radionuclides.镤-225 掺杂的磷灰石纳米颗粒,部分隔离子体放射性核素。
Bioconjug Chem. 2011 Apr 20;22(4):766-76. doi: 10.1021/bc100574f. Epub 2011 Mar 24.